| page | |
| EDITORIALS |
| 404 | Gateway to the lungs: Viral entry receptors and susceptibility to COVID‐19
|
| 406 | Are serum biomarkers useful in the management of systemic sclerosis‐associated interstitial lung disease?
Susanna M Proudman MBBS (Hons), FRACP; Tamera J Corte MBBS, BSc (Med), FRACP, PhD
10.1111/resp.14017 |
| 409 | Springs that don't spring out: Fiducials for stereotactic radiotherapy
|
| 411 | Pharmacotherapy for sleep apnoea: A search for the right therapeutic key
|
| COMMENTARIES |
| 413 | The untreated treatable trait: Cardiovascular disease in COPD exacerbations
|
| 416 | Aerosol‐generating procedures in the COVID era
|
| INVITED REVIEW SERIES |
| 419 | Contemporary perspectives in COPD: Patient burden, the role of gender and trajectories of multimorbidity
Sara C Buttery; Maéva Zysman; Sigrid A A Vikjord; Nicholas S Hopkinson; Christine Jenkins; Lowie E G W Vanfleteren
10.1111/resp.14032 |
| ORIGINAL ARTICLES |
| Asthma and Allergy |
| 442 |
ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma
Peter A B Wark; Prabuddha S Pathinayake; Gerard Kaiko; Kristy Nichol; Ayesha Ali; Ling Chen; Erika N Sutanto; Luke W Garratt; Sukhwinder S Sohal; Wenying Lu; Mathew S Eapen; Christopher Oldmeadow; Nathan Bartlett; Andrew Reid; Punnam Veerati; Alan C‐Y Hsu; Kevin Looi; Thomas Iosifidis; Stephen M Stick; Philip M Hansbro; Anthony Kicic
10.1111/resp.14003
ACE2 is the primary receptor for SARS‐CoV‐2. We demonstrate that lower airway expression of ACE2 is increased in older adults and males. Lower ACE2 expression in epithelial cells also occurs in people with asthma and is associated with reduced furin and increased ADAM‐17 expression. This may partly explain the relative sparing of people with asthma from severe COVID‐19. |
| Interstitial Lung Disease |
| 452 | Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective ‘target trial’ emulated with Swedish real‐world data
Marios Rossides; Susanna Kullberg; Daniela Di Giuseppe; Anders Eklund; Johan Grunewald; Johan Askling; Elizabeth V Arkema
10.1111/resp.14001
The 6‐month infection risk was 43% lower in patients with sarcoidosis who initiated methotrexate compared to those who started azathioprine. Our findings suggest that unless contraindications exist, methotrexate should be preferred over azathioprine as the primary steroid‐sparing choice in individuals with sarcoidosis. |
| 461 | Serum markers of pulmonary epithelial damage in systemic sclerosis‐associated interstitial lung disease and disease progression
Carmel J W Stock; Rachel K Hoyles; Cecile Daccord; Maria Kokosi; Dina Visca; Angelo De Lauretis; Veronica Alfieri; Vasilis Kouranos; George Margaritopoulos; Peter M George; Philip L Molyneaux; Felix Chua; Toby M Maher; David J Abraham; Voon Ong; Jackie Donovan; Piersante Sestini; Christopher P Denton; Athol U Wells; Elisabetta A Renzoni
10.1111/resp.13988
The clinical course of systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) is highly variable and easily measurable biomarkers are needed to predict disease progression. Serum epithelial biomarker KL‐6 is predictive of disease progression measured by a decline in DLCO, regardless of ILD severity, and could provide increased prognostic ability to inform risk stratification in SSc‐ILD. |
| Lung Cancer |
| 469 | Endobronchial coil spring fiducial markers for CyberKnife® stereotactic body radiation therapy
Alessio Casutt; Leslie Noirez; Maurizio; Bernasconi; Angela Koutsokera; Catherine Beigelman‐Aubry; Rémy Kinj; Esat‐Mahmut Ozsahin; André‐Dante Durham; Christophe von Garnier; Alban Lovis
10.1111/resp.14006
We assessed for the first time the safety and efficacy of bronchoscopically inserted cs‐FM for CyberKnife® SBRT delivery. We show that this technique is safe and resulted in a very high PPL tracking rate enabling optimal SBRT delivery. |
| 477 | Cone‐beam computed tomography versus computed tomography‐guided ultrathin bronchoscopic diagnosis for peripheral pulmonary lesions: A propensity score‐matched analysis
Naoya Kawakita; Hiromitsu Takizawa; Hiroaki Toba; Shinichi Sakamoto; Naoki Miyamoto; Daisuke Matsumoto; Mika Takashima; Mitsuhiro Tsuboi; Mitsuteru Yoshida; Yukikiyo Kawakami; Kazuya Kondo; Akira Tangoku
10.1111/resp.14016
Diagnostic yields of CT‐guided and CBCT‐guided transbronchial biopsy for peripheral pulmonary nodules were compared by propensity score‐matched analysis. Overall diagnostic yields were 47.9% for CT‐guided biopsy and 72.9% for CBCT‐guided biopsy. CBCT‐guided biopsy improved the diagnostic yield. |
| Sleep and Ventilation |
| 485 |
Impact of cold and flu medication on obstructive sleep apnoea and its underlying traits: A pilot randomized controlled trial
Luigi Taranto‐Montemurro; Scott Sands; Ali Azarbarzin; Nicole Calianese; Daniel Vena; Lauren Hess; Sang‐Wook Kim; David P White; Andrew Wellman
10.1111/resp.14009
Pseudoephedrine and diphenhydramine, commonly used as over‐the‐counter combination for cold and flu, reduce the collapsibility of the upper airway in patients with OSA but do not reduce the number of obstructions. Their effect is not mediated by pharyngeal muscles stimulation, but most likely by a decongestant effect. |
| CONTEMPORARY CONCISE REVIEW |
| 493 | Contemporary Concise Review 2020: Chronic obstructive pulmonary disease
|
| FORUM AND DEBATE |
| Scientific Letter |
| 501 | Radiological outcomes of whole lung lavage for artificial stone‐associated silicosis
Daniel C Chambers; Simon H Apte; David Deller; Philip J Masel; Catherine M Jones; Katrina Newbigin; Michael Matula; Ivan L Rapchuk
10.1111/resp.14018 |
| Correspondences |
| 504 | Predictive value of blood eosinophil count in COPD
|
| 504 | Reply
Fanny W S Ko MD; Ka Pang Chan MBChB; Jenny Ngai MBChB; So‐Shan Ng MBChB; Wing Ho Yip MBChB; Tat‐On Chan MPhil; David S C Hui MD
10.1111/resp.14024 |
| 507 | Is rigid tracheobronchoscopy safe enough for airway disease?
|
| 507 | Reply
|
| 509 | Provision of essential bronchoscopy during COVID‐19 pandemic
Waheed Shah MB; Orla O'Carroll MD; Michael P Keane MD; Cormac McCarthy MB, PhD
10.1111/resp.14034 |
| 510 | A note on lung cancer in the COVID‐19 era
|
| 511 | Reply
|
| 513 | Letter from Canada: A pandemic that has humbled us?
|
